



RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 10/602,394
Source: FWO
Date Processed by STIC: 12/2/04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
U.S. Patent and Trademark Office, 220 20th Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Raw Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER: 10/602/394

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE

- 1 Wrapped Nucleics
Wrapped Aminos The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
- 2 Invalid Line Length The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 Misaligned Amino
Numbering The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 Non-ASCII The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 Variable Length Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 PatentIn 2.0
"bug" A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s). Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 Skipped Sequences
(OLD RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
(2) INFORMATION FOR SEQ ID NO X (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS (Do not insert any subheadings under this heading)
(ix) SEQUENCE DESCRIPTION SEQ ID NO X (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES" response to include the skipped sequences.
- 8 Skipped Sequences
(NEW RULES) Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
<210> sequence id number
<400> sequence id number
000
- 9 Use of n's or Xaa's
(NEW RULES) Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
- 10 Invalid <213>
Response Per 1.823 of Sequence Rules, the only valid <213> responses are Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence.
- 11 Use of <220> Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 08/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 PatentIn 2.0
"bug" Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 Misuse of n/Xaa "n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid



IFWO

RAW SEQUENCE LISTING

DATE: 12/02/2004

PATENT APPLICATION: US/10/602,394

TIME: 13:02:07

Input Set : A:\UF-375.ST25.txt

Output Set: N:\CRF4\12022004\J602394.raw

3 <110> APPLICANT: Haskell-Luevano, Carrie
 5 <120> TITLE OF INVENTION: Novel Melanocortin Receptor Peptide Template for the
 Treatment of
 6 Obesity
 8 <130> FILE REFERENCE: UF-375
 C--> 10 <140> CURRENT APPLICATION NUMBER: US/10/602,394
 C--> 10 <141> CURRENT FILING DATE: 2003-06-23
 10 <160> NUMBER OF SEQ ID NOS: 43
 12 <170> SOFTWARE: PatentIn version 3.2
 14 <210> SEQ ID NO: 1
 15 <211> LENGTH: 12
 16 <212> TYPE: PRT
 17 <213> ORGANISM: Artificial Sequence
 19 <220> FEATURE:
 20 <223> OTHER INFORMATION: chimeric peptide
 23 <220> FEATURE:
 24 <221> NAME/KEY: MISC_FEATURE
 25 <222> LOCATION: (2)..(2)
 26 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this
 peptide
 27 (begin)
 29 <220> FEATURE:
 30 <221> NAME/KEY: MISC_FEATURE
 31 <222> LOCATION: (6)..(6)
 32 <223> OTHER INFORMATION: Xaa = DPhe
 34 <220> FEATURE:
 35 <221> NAME/KEY: MISC_FEATURE
 36 <222> LOCATION: (11)..(11)
 37 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this
 peptide
 38 (end)
 40 <400> SEQUENCE: 1
 W--> 42 Tyr Xaa Cys Arg Phe Xaa Asn Ala Phe Cys Xaa Tyr
 43 1 5 10
 46 <210> SEQ ID NO: 2
 47 <211> LENGTH: 12
 48 <212> TYPE: PRT
 49 <213> ORGANISM: Artificial Sequence
 51 <220> FEATURE:
 52 <223> OTHER INFORMATION: chimeric peptide
 55 <220> FEATURE:
 56 <221> NAME/KEY: MISC_FEATURE
 57 <222> LOCATION: (2)..(2)
 58 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this

(pg. 7)

Does Not Comply
Corrected Diskette Needed

(pg. 1-6)

Invalid
responseInvalid
response"Xaa" FXI
CAN only
represent a
single amino
acid.See item
#13 on error
summary
sheet.

Invalid Response

peptide

59 (begin)

61 <220> FEATURE:

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/602,394

DATE: 12/02/2004

TIME: 13:02:07

Input Set : A:\UF-375.ST25.txt

Output Set: N:\CRF4\12022004\J602394.raw

62 <221> NAME/KEY: MISC_FEATURE
 63 <222> LOCATION: (10)..(10)
 64 <223> OTHER INFORMATION: Xaa = diaminopropionic acid (Dpr)
 66 <220> FEATURE:
 67 <221> NAME/KEY: MISC_FEATURE
 68 <222> LOCATION: (11)..(11)
 69 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this

peptide

70 (end)

72 <400> SEQUENCE: 2

W--> 74 Tyr Xaa Asp Ala Ala Asn Ala Phe Xaa Xaa Tyr

75 1 5 10

78 <210> SEQ ID NO: 3

79 <211> LENGTH: 12

80 <212> TYPE: PRT

81 <213> ORGANISM: Artificial Sequence

83 <220> FEATURE:

84 <223> OTHER INFORMATION: chimeric peptide

87 <220> FEATURE:

88 <221> NAME/KEY: MISC_FEATURE

89 <222> LOCATION: (2)..(2)

90 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this

peptide

91 (begin)

93 <220> FEATURE:

94 <221> NAME/KEY: MISC_FEATURE

95 <222> LOCATION: (10)..(10)

96 <223> OTHER INFORMATION: Xaa = diaminopropionic acid (Dpr)

98 <220> FEATURE:

99 <221> NAME/KEY: MISC_FEATURE

100 <222> LOCATION: (11)..(11)

101 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this

peptide

102 (end)

104 <400> SEQUENCE: 3

W--> 106 Tyr Xaa Asp Arg Phe Phe Asn Ala Phe Xaa Xaa Tyr

107 1 5 10

110 <210> SEQ ID NO: 4

111 <211> LENGTH: 12

112 <212> TYPE: PRT

113 <213> ORGANISM: Artificial Sequence

115 <220> FEATURE:

116 <223> OTHER INFORMATION: chimeric peptide

119 <220> FEATURE:

120 <221> NAME/KEY: MISC_FEATURE

121 <222> LOCATION: (2)..(2)

122 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this

peptide

123 (begin)

125 <220> FEATURE:

126 <221> NAME/KEY: MISC_FEATURE

127 <222> LOCATION: (10)..(10)

128 <223> OTHER INFORMATION: Xaa = diaminopropionic acid (Dpr)

✓ See item
 #13 on
 error
 summary
 sheet

INVALID
 Response

INVALID
 Response

INVALID
 Response

INVALID
 Response

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/602,394

DATE: 12/02/2004

TIME: 13:02:07

Input Set : A:\UF-375.ST25.txt

Output Set : N:\CRF4\12022004\J602394.raw

See item #13
on error
summary
sheet.

130 <220> FEATURE:

131 <221> NAME/KEY: MISC_FEATURE

132 <222> LOCATION: (11)..(11)

133 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

134 (end)

136 <400> SEQUENCE: 4

W--> 138 Tyr Xaa Asp Trp Arg Phe Asn Ala Phe Xaa Xaa Tyr

139 1 5 10

142 <210> SEQ ID NO: 5

143 <211> LENGTH: 12

144 <212> TYPE: PRT

145 <213> ORGANISM: Artificial Sequence

147 <220> FEATURE:

148 <223> OTHER INFORMATION: chimeric peptide

151 <220> FEATURE:

152 <221> NAME/KEY: MISC_FEATURE

153 <222> LOCATION: (2)..(2)

154 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

155 (begin)

157 <220> FEATURE:

158 <221> NAME/KEY: MISC_FEATURE

159 <222> LOCATION: (6)..(6)

160 <223> OTHER INFORMATION: Xaa = DPhe

162 <220> FEATURE:

163 <221> NAME/KEY: MISC_FEATURE

164 <222> LOCATION: (10)..(10)

165 <223> OTHER INFORMATION: Xaa = diaminopropionic acid (Dpr)

167 <220> FEATURE:

168 <221> NAME/KEY: MISC_FEATURE

169 <222> LOCATION: (11)..(11)

170 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

171 (end)

173 <400> SEQUENCE: 5

W--> 175 Tyr Xaa Asp Trp Arg Xaa Asn Ala Phe Xaa Xaa Tyr

176 1 5 10

179 <210> SEQ ID NO: 6

180 <211> LENGTH: 12

181 <212> TYPE: PRT

182 <213> ORGANISM: Artificial Sequence

184 <220> FEATURE:

185 <223> OTHER INFORMATION: chimeric peptide

188 <220> FEATURE:

189 <221> NAME/KEY: MISC_FEATURE

190 <222> LOCATION: (2)..(2)

191 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

192 (begin)

194 <220> FEATURE:

195 <221> NAME/KEY: MISC_FEATURE

196 <222> LOCATION: (10)..(10)

Invalid
Response

Invalid
Response

Invalid
Response

Invalid
Response

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/602,394

DATE: 12/02/2004

TIME: 13:02:07

Input Set : A:\UF-375.ST25.txt

Output Set: N:\CRF4\12022004\J602394.raw

✓ SAME
errors

197 <223> OTHER INFORMATION: Xaa = diaminopropionic acid (Dpr)

199 <220> FEATURE:

200 <221> NAME/KEY: MISC_FEATURE

201 <222> LOCATION: (11)..(11)

202 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

203 (end)

205 <400> SEQUENCE: 6

W--> 207 Tyr Xaa Asp Phe Arg Trp Asn Ala Phe Xaa Xaa Tyr

208 1 5 10

211 <210> SEQ ID NO: 7

212 <211> LENGTH: 12

213 <212> TYPE: PRT

214 <213> ORGANISM: Artificial Sequence

216 <220> FEATURE:

217 <223> OTHER INFORMATION: chimeric peptide

220 <220> FEATURE:

221 <221> NAME/KEY: MISC_FEATURE

222 <222> LOCATION: (2)..(2)

223 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

224 (begin)

226 <220> FEATURE:

227 <221> NAME/KEY: MISC_FEATURE

228 <222> LOCATION: (4)..(4)

229 <223> OTHER INFORMATION: Xaa = DPhe

231 <220> FEATURE:

232 <221> NAME/KEY: MISC_FEATURE

233 <222> LOCATION: (10)..(10)

234 <223> OTHER INFORMATION: Xaa = diaminopropionic acid (Dpr)

236 <220> FEATURE:

237 <221> NAME/KEY: MISC_FEATURE

238 <222> LOCATION: (11)..(11)

239 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

240 (end)

242 <400> SEQUENCE: 7

W--> 244 Tyr Xaa Asp Xaa Arg Trp Asn Ala Phe Xaa Xaa Tyr

245 1 5 10

248 <210> SEQ ID NO: 8

249 <211> LENGTH: 13

250 <212> TYPE: PRT

251 <213> ORGANISM: Artificial Sequence

253 <220> FEATURE:

254 <223> OTHER INFORMATION: chimeric peptide

257 <220> FEATURE:

258 <221> NAME/KEY: MISC_FEATURE

259 <222> LOCATION: (2)..(2)

260 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

261 (begin)

263 <220> FEATURE:

264 <221> NAME/KEY: MISC_FEATURE

See item
#13 on
error
summary
sheet.

RAW SEQUENCE LISTING

DATE: 12/02/2004

PATENT APPLICATION: US/10/602,394

TIME: 13:02:07

Input Set : A:\UF-375.ST25.txt

Output Set: N:\CRF4\12022004\J602394.raw

✓ same errors

265 <222> LOCATION: (11)..(11)
 266 <223> OTHER INFORMATION: Xaa = diaminopropionic acid (Dpr)
 268 <220> FEATURE:
 269 <221> NAME/KEY: MISC_FEATURE
 270 <222> LOCATION: (12)..(12)
 271 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

272 (end)

274 <400> SEQUENCE: 8

W--> 276 Tyr Xaa Asp His Arg Phe Phe Asn Ala Phe Xaa Xaa Tyr

277 1 5 10

280 <210> SEQ ID NO: 9

281 <211> LENGTH: 13

282 <212> TYPE: PRT

283 <213> ORGANISM: Artificial Sequence

285 <220> FEATURE:

286 <223> OTHER INFORMATION: chimeric peptide

289 <220> FEATURE:

290 <221> NAME/KEY: MISC_FEATURE

291 <222> LOCATION: (2)..(2)

292 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

293 (begin)

295 <220> FEATURE:

296 <221> NAME/KEY: MISC_FEATURE

297 <222> LOCATION: (11)..(11)

298 <223> OTHER INFORMATION: Xaa = diaminopropionic acid (Dpr)

300 <220> FEATURE:

301 <221> NAME/KEY: MISC_FEATURE

302 <222> LOCATION: (12)..(12)

303 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

304 (end)

306 <400> SEQUENCE: 9

W--> 308 Tyr Xaa Asp His Phe Arg Trp Asn Ala Phe Xaa Xaa Tyr

309 1 5 10

312 <210> SEQ ID NO: 10

313 <211> LENGTH: 13

314 <212> TYPE: PRT

315 <213> ORGANISM: Artificial Sequence

317 <220> FEATURE:

318 <223> OTHER INFORMATION: chimeric peptide

321 <220> FEATURE:

322 <221> NAME/KEY: MISC_FEATURE

323 <222> LOCATION: (2)..(2)

324 <223> OTHER INFORMATION: Xaa in this location represents the cyclization of this peptide

325 (begin)

327 <220> FEATURE:

328 <221> NAME/KEY: MISC_FEATURE

329 <222> LOCATION: (5)..(5)

330 <223> OTHER INFORMATION: Xaa = DPhe

332 <220> FEATURE:

See item #13
 on error
 summary
 sheet.

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/602,394DATE: 12/02/2004
TIME: 13:02:08

Input Set : A:\UF-375.ST25.txt

Output Set: N:\CRF4\12022004\J602394.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#:1; Xaa Pos. 2,6,11
Seq#:2; Xaa Pos. 2,10,11
Seq#:3; Xaa Pos. 2,10,11
Seq#:4; Xaa Pos. 2,10,11
Seq#:5; Xaa Pos. 2,6,10,11
Seq#:6; Xaa Pos. 2,10,11
Seq#:7; Xaa Pos. 2,4,10,11
Seq#:8; Xaa Pos. 2,11,12
Seq#:9; Xaa Pos. 2,11,12
Seq#:10; Xaa Pos. 2,5,11,12
Seq#:11; Xaa Pos. 1,5,7,15,16
Seq#:12; Xaa Pos. 1,5
Seq#:13; Xaa Pos. 1,5
Seq#:14; Xaa Pos. 1,5
Seq#:15; Xaa Pos. 1,5
Seq#:16; Xaa Pos. 1,5,8
Seq#:17; Xaa Pos. 1,5,9
Seq#:18; Xaa Pos. 1,5,10
Seq#:19; Xaa Pos. 1,2,3,10
Seq#:20; Xaa Pos. 1,2,3,10
Seq#:21; Xaa Pos. 1,2,3,6,10
Seq#:22; Xaa Pos. 1,2,3,7,10
Seq#:23; Xaa Pos. 1,2,3,8,10
Seq#:24; Xaa Pos. 2,5,11,12
Seq#:25; Xaa Pos. 2,11,12
Seq#:26; Xaa Pos. 2,5,11,12
Seq#:27; Xaa Pos. 2,5,11,12
Seq#:28; Xaa Pos. 2,5,11,12
Seq#:29; Xaa Pos. 2,5,11,12
Seq#:30; Xaa Pos. 2,4,5,11,12
Seq#:31; Xaa Pos. 2,11,12
Seq#:32; Xaa Pos. 2,5,11,12
Seq#:33; Xaa Pos. 2,5,11,12
Seq#:34; Xaa Pos. 2,5,11,12
Seq#:35; Xaa Pos. 2,5,11,12
Seq#:36; Xaa Pos. 2,5,11,12
Seq#:37; Xaa Pos. 2,5,11,12
Seq#:38; Xaa Pos. 2,5,11,12
Seq#:39; Xaa Pos. 2,5,7,11,12
Seq#:40; Xaa Pos. 2,5,7,11,12
Seq#:41; Xaa Pos. 2,5,7,11,12
Seq#:42; Xaa Pos. 2,5,7,11,12
Seq#:43; Xaa Pos. 2,5,10,11,12

VERIFICATION SUMMARY

DATE: 12/02/2004

PATENT APPLICATION: US/10/602,394

TIME: 13:02:08

Input Set : A:\UF-375.ST25.txt

Output Set: N:\CRF4\12022004\J602394.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application No
L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:42 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:0
L:74 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:0
L:106 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3 after pos.:0
L:138 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0
L:175 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:0
L:207 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0
L:244 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0
L:276 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:8 after pos.:0
L:308 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:9 after pos.:0
L:345 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10 after pos.:0
L:392 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11 after pos.:0
L:421 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12 after pos.:0
L:446 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13 after pos.:0
L:471 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14 after pos.:0
L:496 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15 after pos.:0
L:526 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16 after pos.:0
L:556 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17 after pos.:0
L:586 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18 after pos.:0
L:623 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19 after pos.:0
L:660 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20 after pos.:0
L:702 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21 after pos.:0
L:744 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22 after pos.:0
L:786 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23 after pos.:0
L:823 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:24 after pos.:0
L:855 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25 after pos.:0
L:892 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:26 after pos.:0
L:929 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:27 after pos.:0
L:966 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:28 after pos.:0
L:1003 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:29 after pos.:0
L:1045 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:30 after pos.:0
L:1077 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:31 after pos.:0
L:1114 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:32 after pos.:0
L:1151 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:33 after pos.:0
L:1188 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:34 after pos.:0
L:1225 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:35 after pos.:0
L:1262 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:36 after pos.:0
L:1299 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:37 after pos.:0
L:1336 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:38 after pos.:0
L:1378 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:39 after pos.:0
L:1420 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:40 after pos.:0
L:1462 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:41 after pos.:0
L:1504 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:42 after pos.:0
L:1546 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:43 after pos.:0